Production (Stage)
Anika Therapeutics, Inc.
ANIK
$11.24
-$0.53-4.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.84% | 16.15% | -34.61% | -32.45% | -28.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.84% | 16.15% | -34.61% | -32.45% | -28.94% |
| Cost of Revenue | 134.70% | 99.37% | -12.87% | -47.33% | -45.56% |
| Gross Profit | -22.91% | -21.34% | -47.60% | -23.66% | -18.81% |
| SG&A Expenses | 31.56% | 8.99% | -61.04% | -53.57% | -48.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.17% | 40.65% | -43.20% | -49.84% | -45.12% |
| Operating Income | -350.34% | -1,818.59% | 91.24% | 160.64% | 146.19% |
| Income Before Tax | -331.47% | -1,010.33% | 87.76% | 163.65% | 149.01% |
| Income Tax Expenses | -30.57% | -13.30% | 410.87% | 303.20% | 273.83% |
| Earnings from Continuing Operations | -835.62% | -901.69% | 35.98% | 134.31% | 122.24% |
| Earnings from Discontinued Operations | -693.35% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.14% | 31.79% | -296.83% | -234.53% | -244.90% |
| EBIT | -350.34% | -1,818.59% | 91.24% | 160.64% | 146.19% |
| EBITDA | -186.64% | -219.32% | 149.14% | 338.37% | 326.08% |
| EPS Basic | 26.12% | 31.95% | -295.72% | -234.29% | -244.25% |
| Normalized Basic EPS | -292.06% | -737.69% | 99.22% | 175.32% | 158.61% |
| EPS Diluted | 25.96% | 31.90% | -293.49% | -231.33% | -240.87% |
| Normalized Diluted EPS | -292.08% | -737.75% | 99.22% | 175.32% | 158.61% |
| Average Basic Shares Outstanding | -0.33% | 0.43% | 0.59% | 0.42% | 0.39% |
| Average Diluted Shares Outstanding | -0.25% | 0.51% | 0.59% | 0.42% | 0.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |